



**UNITED STATES DEPARTMENT OF COMMERCE**  
**Pat nt and Trademark Office**

Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.
-----------------	-------------	----------------------	---------------------

08/962,040 10/31/97 CARNEY

J

002292 HM12/0329  
BIRCH STEWART KOLASCH & BIRCH  
8110 GATEHOUSE ROAD  
SUITE 500 EAST  
FALLS CHURCH VA 22042

EXAMINER

JONES, D

ART UNIT

PAPER NUMBER

1614

DATE MAILED:

03/29/01

Please find below and/or attached an Office communication concerning this application or proceeding.

Commissioner of Patents and Trademarks

# Office Action Summary

Application No.  
**08/962,040**

Applicant(s)  
**Carney et al.**

Examiner  
**Dwayne C. Jones**

Group Art Unit  
**1614**

☒ Responsive to communication(s) filed on 15 Apr 2000

☐ This action is **FINAL**.

☐ Since this application is in condition for allowance except for formal matters, **prosecution as to the merits is closed** in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11; 453 O.G. 213.

A shortened statutory period for response to this action is set to expire 3 month(s), or thirty days, whichever is longer, from the mailing date of this communication. Failure to respond within the period for response will cause the application to become abandoned. (35 U.S.C. § 133). Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

## Disposition of Claims

☒ Claim(s) 17-51 is/are pending in the application.

Of the above, claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

☐ Claim(s) \_\_\_\_\_ is/are allowed.

☒ Claim(s) 17-51 is/are rejected.

☐ Claim(s) \_\_\_\_\_ is/are objected to.

☐ Claims \_\_\_\_\_ are subject to restriction or election requirement.

## Application Papers

☐ See the attached Notice of Draftsperson's Patent Drawing Review, PTO-948.

☐ The drawing(s) filed on \_\_\_\_\_ is/are objected to by the Examiner.

☐ The proposed drawing correction, filed on \_\_\_\_\_ is ☐ approved ☐ disapproved.

☐ The specification is objected to by the Examiner.

☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. § 119

☐ Acknowledgement is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d).

☐ All ☐ Some\* ☐ None of the CERTIFIED copies of the priority documents have been

☐ received.

☐ received in Application No. (Series Code/Serial Number) \_\_\_\_\_.

☐ received in this national stage application from the International Bureau (PCT Rule 17.2(a)).

\*Certified copies not received: \_\_\_\_\_

☐ Acknowledgement is made of a claim for domestic priority under 35 U.S.C. § 119(e).

## Attachment(s)

☒ Notice of References Cited, PTO-892

☐ Information Disclosure Statement(s), PTO-1449, Paper No(s). \_\_\_\_\_

☐ Interview Summary, PTO-413

☐ Notice of Draftsperson's Patent Drawing Review, PTO-948

☐ Notice of Informal Patent Application, PTO-152

--- SEE OFFICE ACTION ON THE FOLLOWING PAGES ---

Art Unit: 1614

*Status of Claims*

1. Claims 17-51 are pending.
2. Claims 28-51 are elected and rejected.
3. Claims 17-27 are non-elected and withdrawn from consideration.

*Claim Rejections - 35 USC § 101*

4. 35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

5. Claims 17-51 are rejected under 35 U.S.C. 101 because the claimed invention is not supported by either a credible asserted utility or a well established utility.
6. In this rejection is presumed that applicants intend to prevent or retard physiological aging and not chronological aging, since the latter reads on the stoppage of time, which is not credible on its face. The preventing or retarding of aging via systemic treatment is itself not credible on its face in view of contemporary knowledge in the art. No compound is currently known which would have these effects.
7. Physiological aging is a multi-faceted process which does not involve a single chemical or biological effect. Various theories have been propounded (see Lehninger et al., pages 341, 344 )

Art Unit: 1614

including (1) loss of telomerase activity and the relationship of telomerase activity and the relationship of telomere length to cell death, (2) accumulation of DNA mutations, and (3) temporal genes which regulate the output of structural genes. In view of these theories, one skilled in the art would conclude that the diverse aspects of aging, e.g. loss of muscle tone, slowing of metabolism, greying of hair, etc. operate via different mechanisms. There is no reason why one skilled in the art would expect a single compound to prevent or retard all of these diverse aspects.

8. A systemic anti-aging utility has been alleged in U.S. Patent No. 5,157,031, but that utility is neither exemplified nor claimed therein. Furthermore, since the claims 28-51 are directed to methods, the utility is limited to those recited methods and there is no non-asserted well established utility for such methods.

***Claim Rejections - 35 USC § 112***

9. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

10. Claims 17-51 are rejected under 35 U.S.C. 112, first paragraph, since the specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make or use the invention. Specifically, since the claimed invention is not supported by either a credible asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention. The

Art Unit: 1614

specification does not provide support or guidance to make or use trapping compounds to prevent or treat aging. Furthermore, the specification fails to provide support or guidance to treat a patient suffering from a dysfunction or a disease condition arising from oxidative damage, such as with Parkinson's disease, with derivatives of alpha-phenyl-N-phenylnitrone. Without such information, one skilled in the art could not predict which analogs or prodrugs out of the vast numbers of potential derivatives would react to treat, let alone prevent, the litany of diseases which are purported to be treated let alone prevented with the administration of alpha-phenyl-N-phenylnitrone. Accordingly, one skilled in the art would be required to perform undue experimentation to identify any *other* derivatives which could be used in conjunction with the spin trapping compounds to treat, let alone prevent, various disease resulting from oxidative damage. And so, one skilled in the art could not make or use the invention without undue experimentation.

***Claim Rejections - 35 USC § 102***

11. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

12. Claims 17-27 are rejected under 35 U.S.C. 102(b) as being clearly anticipated by Campbell et al. of U.S. Patent No. 4,153,722. Campbell et al. teach of the administration of alpha-phenyl-


Art Unit: 1614

N-phenylnitron and derivatives thereof. Note that composition claims are not deemed to be limited by an "intended use", see In re Hack 114 USPQ 161.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to D. C. Jones whose telephone number is (703) 308-4634. The examiner can normally be reached on Mondays through Fridays from 8:30 am to 6:00 pm. The examiner can also be reached on alternate Mondays.

The fax phone number for the organization where this application or proceeding is assigned is (703) 308-4556.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1235.

  
DWS/D.C. JONES  
PRIMARY EXAMINER  
Tech. Ctr. 1614  
March 23, 2001